Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea

L A Styles1, B Lubin, E Vichinsky

  • 1Department of Hematology/Oncology, Children's Hospital, Oakland, CA 94609, USA.

Blood
|April 1, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

[Effect analysis of short-term spinal cord stimulation on segmental zoster paralysis of limbs].

Zhonghua yi xue za zhi·2025
Same author

Post-caesarean analgesia: a multicentre retrospective analysis comparing practices in Queensland, Australia (2019-2022).

International journal of obstetric anesthesia·2025
Same author

[Efficacy of spinal cord stimulation in the treatment of lower extremity peripheral arterial disease].

Zhonghua yi xue za zhi·2025
Same author

[Bardoxolone methyl alleviates acute liver injury in mice by inhibiting NLRP3 inflammasome activation].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2024
Same author

Placement, management and complications associated with peripheral intravenous catheter use in UK small animal practice.

The Journal of small animal practice·2024

Hydroxyurea therapy for sickle cell disease (SCD) reduces vaso-occlusion by decreasing adhesion receptors very late activation antigen-4 (VLA-4) and CD36 on sickle red blood cells. This receptor modulation occurs independently of reticulocyte count changes.

Area of Science:

  • Hematology
  • Vascular Biology
  • Pharmacology

Background:

  • Sickle cell disease (SCD) involves vaso-occlusive events linked to abnormal red blood cell adhesion.
  • Very late activation antigen-4 (VLA-4) and CD36 are key adhesion receptors on sickle reticulocytes mediating this adhesion.

Purpose of the Study:

  • To investigate if hydroxyurea (HU) therapy, known to reduce SCD clinical severity, modulates VLA-4 and CD36 expression on sickle red blood cells.

Main Methods:

  • Flow cytometry was used to track VLA-4 and CD36 expression on reticulocytes in eight SCD patients undergoing HU treatment.
  • Patients were monitored for a mean of 200 days, with changes correlated to treatment duration and fetal hemoglobin (Hb F) levels.

Main Results:

Related Experiment Videos

  • HU treatment significantly decreased VLA-4 expression from 29.0% to 14.9% and CD36 expression from 55.3% to 42.6%.
  • VLA-4 expression changes occurred before significant increases in Hb F and were not due to reduced reticulocytosis.
  • This is the first study to link decreased adhesion receptor expression to HU therapy's clinical benefits in SCD.

    • Conclusions:

    • Hydroxyurea therapy effectively reduces VLA-4 and CD36 expression on sickle reticulocytes.
    • The modulation of these adhesion receptors likely contributes to the clinical efficacy of HU in reducing vaso-occlusive episodes in SCD.